We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Amarin Corp | AMRN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 92.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 92.50 | 92.50 |
| Top Posts |
|---|
Posted at 11/8/2013 19:36 by someuwin Leerink maintains Outperform on Amarin* Leerink Swann maintains its Outperform rating on shares of Amarin (AMRN) following the company's Q2 report. * Analyst Joseph Schwartz expects "approval of Vascepa for mixed-dyslipidemia" come December 20 (the PDUFA date). * Price target is nonetheless adjusted down to $18 from $20. |
Posted at 15/7/2013 21:04 by someuwin "3 Biotech Stocks That Could Double by Next Summer1. Amarin (NASDAQ: AMRN ) Amarin's stock has dropped like a sinking fastball over the past year. Shares are down more than 60% since last summer and around 30% year-to-date. The steep decline stems largely from Amarin tackling commercialization of Vascepa on its own. At least at first glance, the odds that shares could double by next summer seem slim at best. What looking at the stock's chart doesn't reveal, though, is that Amarin expects a huge decision by the Food and Drug Administration by Dec. 20. The FDA will determine whether the company's highly concentrated fish oil drug Vascepa can be marketed for treating patients with high triglyceride levels between 200 mg/dL and 499 mg/dL. Amarin already won regulatory approval for selling Vascepa for super-high triglyceride levels of 500 mg/dL and above. However, the potential market size that would open up if the FDA grants approval in December is 10 times the size of the company's market available currently. The average analysts' price target for Amarin, according to Thomson/First Call, is $16.50 -- more than triple the stock's price now." Company website: |
Posted at 22/2/2008 10:40 by grahambr Check out AMRN on NASDAQ and you will see RNS 25/1/2008 not shown over here. Recommended as a speculative buy target $7. |
Posted at 26/4/2007 11:00 by bmw30csl just go to yahoo.com finance and enter the symbol amrn. |
Posted at 24/4/2007 14:30 by pomp circumstance OUCH BABY!!!!LONDON, United Kingdom, March 15, 2007, as required under applicable stock exchange regulations, Amarin Corporation plc (NASDAQ: AMRN) ("Amarin" or "Company") announces that Dr Simon Kukes, a non-executive member of the Board of Directors of Amarin, made a market purchase of 285,000 American Depositary Shares ("ADSs") of Amarin on March 14, 2007 at an average price per ADS of $2.40. Following this purchase and the other purchase of 500,000 ADSs by Dr Kukes earlier this week announced on March 13, 2007, Dr Kukes now holds 8,274,212 ADSs of Amarin which represent 9.12% of the issued share capital of the Company. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
